

A randomised phase II trial to compare the toxicity, tolerability and activity of 2-drug combinations of the nucleoside analogue reverse transcriptase inhibitors (NRTIs) lamivudine ((-)-2'-deoxy-3'thiacytidine, 3tc), zidovudine (ZDV) and 1592U89

Submission date 03/10/2000	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 03/10/2000	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 07/11/2022	Condition category Infections and Infestations	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Diana Gibb

Contact details
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA
+44 (0)20 7670 4709
d.gibb@ctu.mrc.ac.uk

Additional identifiers

Protocol serial number
G9627716

Study information

Scientific Title

A randomised phase II trial to compare the toxicity, tolerability and activity of 2-drug combinations of the nucleoside analogue reverse transcriptase inhibitors (NRTIs) lamivudine ((-) 2'-deoxy-3'-thiacytidine, 3tc), zidovudine (ZDV) and 1592U89

Acronym

PENTA 5

Study objectives

Primary:

1. To compare the toxicity, tolerability and activity of three different 2-drug NRTI combinations in children taking either NFV or NFV placebo in Part A, and in those taking NFV in Part B. Activity will be assessed by effect on viral load measured by plasma HIV-1 RNA
2. To assess the tolerability and toxicity of NFV and NFV placebo in children in Part A

Secondary:

1. To compare the activity of NFV and NFV placebo in children taking one of the three 2-drug combinations in Part A
2. To describe the effect on viral resistance, CD4 cell count and clinical progression separately for the three NRTI groups and the NFV and NFV placebo groups
3. To compare the plasma viral load as measured by HIV-1 RNA in the 1592-containing arms with that in the non-1592 arms in children taking NFV or NFV placebo

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Not Specified

Health condition(s) or problem(s) studied

Human Immunodeficiency Virus (HIV), Acquired Immunodeficiency Syndrome (AIDS)

Interventions

Three different 2-drug nucleoside analogue reverse transcriptase inhibitors (NRTI) combinations in children taking either nelfinavir (NFV) or nelfinavir (NFV) placebo

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

1. To compare the combination of two NRTIs plus a protease inhibitor (PI) versus two NRTIs plus a non-nucleoside reverse transcriptase inhibitor (NNRTI) as initial therapy, followed by second-line therapy if virologic failure occurs, in terms of their effects on a long-term virologic endpoint
2. To compare two different viral load criteria for switching from first-line to second-line therapy

Key secondary outcome(s)

1. To evaluate and compare the safety and tolerability of each drug combination (including first- and second-line therapies)
2. To compare the long-term clinical and immunologic outcomes (by the initial randomization)
3. To compare the proportions of children who have undergone one regimen switch or reached study end-point (by the initial randomization)
4. To compare time from randomization to virologic failure (RNA >400 copies/ml at or after week 24) of the first-line therapy analyzed by initial randomization to either protease inhibitor (PI) or NNRTI containing regimens
5. To compare time from randomization to virologic failure of the second line therapy (RNA >30,000 copies/ml) analyzed by the initial randomization
6. To compare the proportion of children with plasma HIV-1 RNA <400 copies/ml at 4 years (by the initial randomization)
7. To describe resistance patterns at 4 years (by the initial randomization)

Completion date

31/07/1999

Eligibility**Key inclusion criteria**

1. 3 months to 16 years of age
2. Definitive HIV-1 infection

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

23/01/1998

Date of final enrolment

31/07/1999

Locations

Countries of recruitment

United Kingdom

England

Study participating centre**MRC Clinical Trials Unit**

London

United Kingdom

NW1 2DA

Sponsor information

Organisation

Medical Research Council (MRC) (UK)

Funder(s)

Funder type

Research council

Funder Name

Medical Research Council (UK)

Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		02/03/2002		Yes	No
Results article		01/08/2002		Yes	No
Other publications		15/04/2000		Yes	No
Other publications		01/09/2001		Yes	No
Other publications		27/09/2002		Yes	No
Other publications	Adherence to prescribed antiretroviral therapy	01/01/2003		Yes	No
Other publications	5 year follow up	11/05/2007		Yes	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes